敌噁磷 | 78-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 敌噁磷
• 中文别名: 敌恶磷；环氧硫磷；二恶磷；二恶硫磷；敌杀磷；虫满敌
• 英文名称: dioxathion
• 英文别名: RuPhos；(3-diethoxyphosphinothioylsulfanyl-1,4-dioxan-2-yl)sulfanyl-diethoxy-sulfanylidene-λ5-phosphane
• CAS: 78-34-2
• 化学式: C₁₂H₂₆O₆P₂S₄
• 分子量: 456.546
• InChiKey: VBKKVDGJXVOLNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  170
• 氢给体数：
  0
• 氢受体数：
  10

ADMET

代谢

当在牛的皮肤上使用时...色谱自动放射性检测显示，二乙基磷酸、二乙基磷硫代酸和二乙基磷二硫代酸是水解的主要产物。还发现了顺式和反式二氧硫磷、二氧杂环醚衍生物...高度极性的化合物...被认为是磷酸...二氧硫磷在植物表面缓慢水解，但一旦被植物吸收就会迅速水解。

WHEN APPLIED DERMALLY TO CATTLE...CHROMATOGRAPHY AUTORADIOGRAPHY SHOWED THAT DIETHYL PHOSPHORIC, DIETHYL PHOSPHOROTHIOIC, & DIETHYL PHOSPHORODITHIOIC ACIDS WERE MAJOR PRODUCTS OF HYDROLYSIS. CIS & TRANS DIOXATHION, DIOXANE DERIV...ALSO FOUND. HIGHLY POLAR CMPD...WAS PRESUMED TO BE PHOSPHORIC ACID... DIOXATHION WAS HYDROLYZED SLOWLY ON PLANT SURFACE BUT HYDROLYZED RAPIDLY WHEN ABSORBED INTO PLANT.

来源:Hazardous Substances Data Bank (HSDB)

代谢

在美国蟑螂和通过大鼠肝脏切片中...二氧噻吩的成分显然被降解为...O,O-二乙基硫代磷酰和二硫代酸。

IN AMERICAN COCKROACH & BY RAT LIVER SLICES...CONSTITUENTS OF DIOXATHION APPARENTLY...DEGRADED TO...O,O-DIETHYL PHOSPHOROTHIOIC & DITHIOIC ACIDS.

来源:Hazardous Substances Data Bank (HSDB)

代谢

在肝微粒体-NADPH系统中，大鼠迅速而广泛地代谢了二噁硫磷的顺式和反式异构体，并且在大鼠体内，通过氧化硫磷基团，形成氧代硫代磷酸酯和二氧代硫代磷酸酯。

TRANS & CIS ISOMERS OF DIOXATHION ARE RAPIDLY & EXTENSIVELY METABOLIZED IN RAT LIVER MICROSOME-NADPH SYSTEMS & IN VIVO, IN RATS BY OXIDN OF THIONOPHOSPHORUS MOIETY, FORMING OXONS & DIOXONS.

来源:Hazardous Substances Data Bank (HSDB)

代谢

当应用于一头赫勒福德牛时，delnav被降解，尿液分析表明存在二乙基磷酸、二乙基硫代磷酸和二乙基亚磷酸。除毛发、皮肤和肝脏外，施用后7天的组织残留物低于0.5 ppm。

When applied to a Hereford steer, delnav was degraded and analysis of urine indicated the presence of diethyl phosphoric acid, diethyl phosphorothioic acid, and diethyl phosphorodithioic acid. With the exception of hair, hide and liver, tissue residues 7 days after application were less than 0.5 ppm.

来源:Hazardous Substances Data Bank (HSDB)

代谢

更多毒性较大的顺式异构体代谢速度更快，不仅形成氧硫和二氧硫，而且从标记的乙氧基团形成(14)-CO2。

The more toxic cis-isomer is metabolized more rapidly not only to form oxon and dioxon but also to form (14)-CO2 from the labeled ethoxy group.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

A4；不可归类为人类致癌物。

A4; Not classifiable as a human carcinogen.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 暴露途径

该物质可以通过吸入其气溶胶、通过皮肤和经口摄入被身体吸收。

The substance can be absorbed into the body by inhalation of its aerosol, through the skin and by ingestion.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 暴露途径

吸入，皮肤吸收，吞食，皮肤和/或眼睛接触

inhalation, skin absorption, ingestion, skin and/or eye contact

来源:The National Institute for Occupational Safety and Health (NIOSH)

毒理性

• 症状

眼睛刺激，皮肤刺激；头痛，头晕，乏力（无力，疲惫）；流鼻涕（流出稀薄鼻涕），胸闷；瞳孔缩小；恶心，呕吐，腹痛，腹泻，流涎；肌肉颤动；混乱，嗜睡

irritation eyes, skin; headache, dizziness, lassitude (weakness, exhaustion); rhinorrhea (discharge of thin nasal mucus), chest tightness; miosis; nausea, vomiting, abdominal cramps, diarrhea, salivation; muscle fasciculation; confusion, drowsiness

来源:The National Institute for Occupational Safety and Health (NIOSH)

毒理性

• 吸入症状

瞳孔收缩，肌肉痉挛，过度流涎。出汗。恶心。头晕。呼吸困难。抽搐。失去意识。

Pupillary constriction, muscle cramp, excessive salivation. Sweating. Nausea. Dizziness. Laboured breathing. Convulsions. Unconsciousness.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

吸收、分配和排泄

当二氧硫磷应用于牛的皮肤时，它会迅速吸收进入血液，放射性活性的峰值在3小时内达到；而在口服处理的动物中，它在12小时内发生。应用后，血液中的放射性活性至少持续1周。尿液的放射性模式跟随血液的放射性模式...

WHEN APPLIED DERMALLY TO CATTLE, DIOXATHION WAS ABSORBED INTO BLOOD RAPIDLY & PEAK LEVEL OF RADIOACTIVITY WAS REACHED IN 3 HR; WHEREAS, IN ORALLY TREATED ANIMALS, IT OCCURRED IN 12 HR. BLOOD RADIOACTIVITY PERSISTED @ LEAST 1 WK AFTER APPLICATION. RADIOACTIVITY PATTERN OF URINE FOLLOWED THAT OF BLOOD...

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

从尿液中回收的比例很高（20.4%），并且在涂抹（32）-P-二氧噻磷后的7天内，从牛的粪便中检测到了微量。在脂肪中发现了少量未代谢的二氧噻磷。

A high proportion (20.4%) was recovered from the urine, and traces were recovered from the feces of a steer within 7 days after dermal application of (32)-P-dioxathion. A small proportion of dioxathion, mainly unmetabolized, was found in the fat...

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  敌噁磷 在 tris-(dibenzylideneacetone)dipalladium(0) 作用下， 以80%的产率得到tert-butyl 6-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylpyrazolo[1,5-a]pyridin-5-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate
  参考文献：
  名称：

  AUTOTAXIN INHIBITORS AND USES THEREOF

  摘要：

  本文描述了用于治疗与自体磷脂酶活性相关的疾病、疾病或疾病的方法和组合物。本文披露的方法和组合物包括至少一种自体磷脂酶抑制剂化合物的使用。

  公开号：

  US20190367515A1
• 作为产物：
  描述：

  二硫代磷酸二乙酯 、 2,3-二氯对二噁烷 生成 敌噁磷
  参考文献：
  名称：

  MINN, J.

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-乙烯基己内酰胺 在 palladium diacetate 敌噁磷 、 caesium carbonate 作用下， 以 水 、 甲苯 为溶剂， 反应 12.0h， 生成 4-(2-(2-oxoazepan-1-yl)ethyl)benzonitrile
  参考文献：
  名称：

  β-Aminoethyltrifluoroborates:  Efficient Aminoethylations via Suzuki−Miyaura Cross-Coupling

  摘要：

  A set of phenethylamines has been successfully prepared via Suzuki-Miyaura cross-coupling of diverse potassium beta-aminoethyltrifluoroborates with aryl halides. The potassium beta-aminoethyltrifluoroborates were easily prepared via hydroboration of enamine and enamide precursors.

  DOI：

  10.1021/ol062610v

文献信息

• [EN] 2-QUINOLONE DERIVED INHIBITORS OF BCL6<br/>[FR] INHIBITEURS DE BCL6 DÉRIVÉS DE 2-QUINOLONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018215798A1

  公开（公告）日：2018-11-29

  The present invention relates to compounds of formula I that function as inhibitors of BCL6(B- cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer,as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及作为BCL6（B细胞淋巴瘤6）活性抑制剂的I式化合物：式中X1、X2、X3、R1、R2、R3、R4和R5分别如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病（如癌症）以及其他BCL6活性所涉及的疾病或病况中的用途。
• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。
• [EN] HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS<br/>[FR] MODULATEURS DU RÉCEPTEUR HORMONAL POUR LE TRAITEMENT D'ÉTATS ET DE TROUBLES MÉTABOLIQUES MUTAGÈNES ET FIBROTIQUES
  申请人：ARDELYX INC

  公开号：WO2019055808A1

  公开（公告）日：2019-03-21

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, Y1, Y2, Y3, Y4, R1, R2, and R3 are described herein.

  这项发明涉及FXR的激活剂，可用于治疗自身免疫性疾病、肝病、肠道疾病、肾脏疾病、癌症以及FXR发挥作用的其他疾病，其化学式为（I）：其中L1、A、X1、X2、Y1、Y2、Y3、Y4、R1、R2和R3如本文所述。
• Thieno-pyrimidine compounds having fungicidal activity
  申请人：Brewster Kirkland William

  公开号：US20070093498A1

  公开（公告）日：2007-04-26

  The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.

  本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。

表征谱图